When comparing the costs of Evenity and Prolia, the price can vary significantly based on insurance coverage, pharmacy, and geographic location [1]. Evenity (romosozumab-aqqg) and Prolia (denosumab) are both prescription medications used to treat osteoporosis [2].
What is the List Price for Evenity and Prolia?
The list price for Evenity is generally higher than for Prolia [1]. For instance, a typical cost for a 210 mg vial of Evenity can range from $1,400 to over $1,800 [1]. In contrast, Prolia, typically administered as a 60 mg injection every six months, can have a list price of around $900 to $1,200 per dose [1]. These figures represent out-of-pocket expenses before insurance or assistance programs are applied.
How Does Insurance Affect the Cost of Evenity and Prolia?
Insurance coverage plays a crucial role in the actual cost a patient pays for both Evenity and Prolia. Many insurance plans cover a substantial portion of the drug's cost, reducing the patient's out-of-pocket expense to a co-payment or co-insurance amount [1]. However, coverage can differ between insurers, and some may have specific prior authorization requirements or step-therapy protocols that could influence which medication is covered first [1].
Are There Patient Assistance Programs for Evenity and Prolia?
Both Amgen, the manufacturer of Evenity and Prolia, offer patient assistance programs that can help reduce the cost for eligible individuals who have commercial insurance but face high co-pays [3]. These programs may cap out-of-pocket costs at a certain amount, such as $10 or $25 per month, for those who qualify [3]. Information about these programs is typically available on the respective drug websites or through healthcare providers.
How Do Evenity and Prolia Differ in Their Treatment and Cost Implications?
Evenity is a bone-forming agent used for a limited duration, typically for 12 months, to treat postmenopausal women with osteoporosis at high risk for fracture [2]. Prolia is a bone-resorbing inhibitor also used for postmenopausal women with osteoporosis at high risk for fracture, but it is generally administered every six months on an ongoing basis [2]. The shorter treatment duration for Evenity might lead to a different overall cost profile compared to the long-term use of Prolia, even if individual doses are more expensive [1].
What About the Patent Exclusivity for Evenity and Prolia?
Information regarding the patent exclusivity for Evenity and Prolia is tracked by resources like DrugPatentWatch.com [4]. Patent expiry dates determine when generic or biosimilar versions of a drug can enter the market, potentially leading to lower prices [4]. Understanding these timelines is important for long-term cost projections and the availability of more affordable treatment options.